Purpose: The purpose of our study was to investigate the cellular accumulation, DNA cross-linking ability, and cellular toxicity of RH1 (2,5-diaziridinyl-3-[hydroxymethyl[-6-methyl-1,4-benzoquinone), a novel DNA alkylating agent currently in clinical trials. In addition, the in vivo efficacy of RH1 formulated in different vehicles was also compared.Experimental Design: RH1 is activated by the two-electron reducing enzyme NQO1 [NAD(P)H:quinone oxidoreductase] forming a potent cytotoxic agent that cross-links DNA. We have used whole blood, cell lines, and primary explanted tumor cultures to measure both the cellular accumulation, DNA cross-linking, and cytotoxicity of RH1. Furthermore, the pharmacokinetic and pharmacodynamic characteristics o...
NoThe indolequinone compound EO9 has good pharmacodynamic properties in terms of bioreductive activa...
The indolequinone compound EO9 has good pharmacodynamic properties in terms of bioreductive activati...
The DNA breakage effect of the anticancer agent 3,6-diaziridinyl-2,5-bis(carboethoxyamino)-1,4-benzo...
Purpose: The purpose of our study was to investigate the cellular accumulation, DNA cross-linking ab...
Background: this trial describes a first-in-man evaluation of RH1, a novel bioreductive drug activat...
2,5-Diaziridinyl-3-(hydroxymethyl)-6-methyl-1,4-benzoquinone (RH1) is a novel antitumor diaziridinyl...
RH1 (2,5-diaziridinyl-3-(hydroxylmethyl)-6-methyl-1,4-benzoquinone) has shown preferential activity ...
This work is concerned with the action of two different anticancer drugs which canalkylate DNA in tu...
One of the widely used chemotherapy to treat cancer is DNA cross-linking agent. Cross-linking is whe...
DNA-damaging agents are widely used in cancer treatment despite their lack of tumor specificity. Hum...
This work is concerned with the synthesis and potential anti-tumour properties of novelDiaziridinylq...
The anticancer activity of aziridinyl-quinones is mainly attributed to their NAD(P)H:quinone oxidore...
NAD(P)H:quinone oxidoreductase-1 (NQO1) is a potential target for therapeutic intervention but attem...
NoNAD(P)H:quinone oxidoreductase-1 (NQO1) is a potential target for therapeutic intervention but att...
Previous studies have indicated that NAD(P)H:quinone oxi-doreductase [DT-diaphorase (NQO1)] plays an...
NoThe indolequinone compound EO9 has good pharmacodynamic properties in terms of bioreductive activa...
The indolequinone compound EO9 has good pharmacodynamic properties in terms of bioreductive activati...
The DNA breakage effect of the anticancer agent 3,6-diaziridinyl-2,5-bis(carboethoxyamino)-1,4-benzo...
Purpose: The purpose of our study was to investigate the cellular accumulation, DNA cross-linking ab...
Background: this trial describes a first-in-man evaluation of RH1, a novel bioreductive drug activat...
2,5-Diaziridinyl-3-(hydroxymethyl)-6-methyl-1,4-benzoquinone (RH1) is a novel antitumor diaziridinyl...
RH1 (2,5-diaziridinyl-3-(hydroxylmethyl)-6-methyl-1,4-benzoquinone) has shown preferential activity ...
This work is concerned with the action of two different anticancer drugs which canalkylate DNA in tu...
One of the widely used chemotherapy to treat cancer is DNA cross-linking agent. Cross-linking is whe...
DNA-damaging agents are widely used in cancer treatment despite their lack of tumor specificity. Hum...
This work is concerned with the synthesis and potential anti-tumour properties of novelDiaziridinylq...
The anticancer activity of aziridinyl-quinones is mainly attributed to their NAD(P)H:quinone oxidore...
NAD(P)H:quinone oxidoreductase-1 (NQO1) is a potential target for therapeutic intervention but attem...
NoNAD(P)H:quinone oxidoreductase-1 (NQO1) is a potential target for therapeutic intervention but att...
Previous studies have indicated that NAD(P)H:quinone oxi-doreductase [DT-diaphorase (NQO1)] plays an...
NoThe indolequinone compound EO9 has good pharmacodynamic properties in terms of bioreductive activa...
The indolequinone compound EO9 has good pharmacodynamic properties in terms of bioreductive activati...
The DNA breakage effect of the anticancer agent 3,6-diaziridinyl-2,5-bis(carboethoxyamino)-1,4-benzo...